Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

@article{Rytting2014AugmentedBT,
  title={Augmented Berlin-Frankfurt-M{\"u}nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).},
  author={Michael Rytting and Deborah A. Thomas and Susan O'brien and Farhad Ravandi-Kashani and Elias J Jabbour and Anna R K Franklin and Tapan M Kadia and Naveen Pemmaraju and Naval G Daver and Alessandra Ferrajoli and Guillermo Garcia-Manero and Marina Y Konopleva and Jorge E. Cortes and Gautham Borthakur and Rebecca S Garris and Maria Cardenas-Turanzas and Kurt Schroeder and Jeffrey L. Jorgensen and Steven M. Kornblau and Hagop M Kantarjian},
  journal={Cancer},
  year={2014},
  volume={120 23},
  pages={3660-8}
}
BACKGROUND Various trials have reported improved outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) who received treatment with pediatric-based regimens. Those reports prompted the current investigation of the pediatric augmented Berlin-Frankfurt-Münster (ABFM) regimen in AYA patients. The results were compared with those from a similar population that received the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…